Trial Profile
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Fludarabine; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; B-cell prolymphocytic leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 01 Sep 2021 Status changed from active, no longer recruiting to completed.
- 24 Jul 2020 Planned primary completion date changed from 20 Aug 2020 to 31 Dec 2020.
- 24 Feb 2020 Planned End Date changed from 30 Aug 2020 to 31 Dec 2020.